Epigenetic Inactivation of EFEMP1 Is Associated with Tumor Suppressive Function in Endometrial Carcinoma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yang, Tingting ^a,b   Qiu, Haifeng ^b   Bao, Wei ^b   Li, Bilan ^b   Lu, Cong ^a   Du, Guiqiang ^a   Luo, Xin ^b   Wang, Lihua ^b   Wan, Xiaoping ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI CHILDREN S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GELATINASE A; GELATINASE B; TRICHOSTATIN A; UVOMORULIN; VIMENTIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CARCINOGENESIS; CARCINOMA CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EFEMP1 GENE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CADHERINS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; VIMENTIN;

MUS MUSCULUS;

EID: 84879520368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067458     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Zhang Y, Liu Z, Yu X, Zhang X, Lu S, et al. (2010) The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 117: 41-46.
3. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, et al. (2007) Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 26: 1971-1982.
4. Bokhman JV, (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17.
5. Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, et al. (2012) Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene.
6. Feinberg AP, Tycko B, (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
7. Dawson MA, Kouzarides T, (2012) Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27.
8. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
9. Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, et al. (2012) Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 7: e32941.
10. Nishimura M, Saito T, Yamasaki H, Kudo R, (2003) Suppression of gap junctional intercellular communication via 5′ CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis 24: 1615-1623.
11. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, et al. (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91: 22-26.
12. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, et al. (2003) Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9: 2277-2287.
13. Wu H, Chen Y, Liang J, Shi B, Wu G, et al. (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438: 981-987.
14. Timpl R, Sasaki T, Kostka G, Chu ML, (2003) Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4: 479-489.
15. de Vega S, Iwamoto T, Yamada Y, (2009) Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66: 1890-1902.
16. Weedon MN, Lango H, Lindgren CM, Wallace C, Evans DM, et al. (2008) Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 40: 575-583.
17. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, et al. (2007) A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 282: 11805-11816.
18. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, et al. (2009) EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7: 189-198.
19. En-lin S, Sheng-guo C, Hua-qiao W, (2010) The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 117: 417-422.
20. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, et al. (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124: 1727-1735.
21. Yu X, Liu L, Cai B, He Y, Wan X, (2008) Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 99: 543-552.
22. Prunier C, Howe PH, (2005) Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT). J Biol Chem 280: 17540-17548.
23. Daniel Kaemmerer LP, Amelie Lupp, Stefan Schulz, Jörg Sänger, (2012) et.al (2012) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5(3): 187-194.
24. Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF, (2002) Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem 277: 27367-27377.
25. Zhan Y, Wang J, Ma Y, Liu Z, Xu H, et al. (2013) Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. Int J Cancer 132: 411-416.
26. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, et al. (2011) EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17: 4523-4530.
27. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, et al. (2007) Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13: 4336-4344.
28. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS, (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271.
29. Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawana K, et al. (2013) The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer 23: 288-293.
30. Harvey I. Pass SML, Michael R Harbut, Melamed, Luis Chiriboga, et al. (2012) Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma. N Engl J Med 367: 1417-1427.
31. Bhakat KK, Mitra S, (2003) CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 24: 1337-1345.
32. Rudolf Jaenisch AB, (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. nature 33: 245-254.
33. Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, et al. (2007) Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 73: 1297-1307.
34. Julie Cannuyer AL, Grégory K Parvizi, Charles De Smet, (2013) Epigenetic Hierarchy within the MAGEA1 Cancer-Germline Gene: Promoter DNA Methylation Dictates Local Histone Modifications. PLOS ONE 8: e58743.
35. Geho DH, Bandle RW, Clair T, Liotta LA, (2005) Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) 20: 194-200.
36. Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, et al. (2012) Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol 43: 632-643.
37. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B, (2004) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 279: 30469-30473.
38. van der Horst PH, Wang Y, Vandenput I, Kuhne LC, Ewing PC, et al. (2012) Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One 7: e30840.
39. Brown AC, Fiore VF, Sulchek TA, Barker TH, (2013) Physical and chemical microenvironmental cues orthogonally control the degree and duration of fibrosis-associated epithelial-to-mesenchymal transitions. J Pathol 229: 25-35.